Invasive candidiasis in cancer patients: observations from a randomized clinical trial - PubMed (original) (raw)
Clinical Trial
Invasive candidiasis in cancer patients: observations from a randomized clinical trial
Mark J DiNubile et al. J Infect. 2005 Jun.
Abstract
Background: Invasive candidiasis is a common and serious complication of cancer and its therapy.
Methods: We retrospectively identified patients with malignancies enrolled in a double-blind randomized trial of caspofungin (50 mg/day after a 70 mg loading dose) vs. conventional amphotericin B (0.6-1.0 mg/kg/day) as treatment of documented invasive candidiasis. A favorable response required complete resolution of signs and symptoms plus eradication of the Candida pathogen(s). The primary efficacy analysis used a modified intention-to-treat (MITT) approach that included all patients with a confirmed diagnosis of invasive candidiasis who received > or =1 dose of study medication.
Results: 74/224 (33%) patients in the MITT population had active malignancies. 25/30 (83%) hematological malignancies were acute or chronic leukaemias. 22/44 (50%) solid tumors were related to the gastrointestinal tract. Patients with hematological malignancies tended to be younger (median [range] age: 49 [19-74] vs. 59 [19-81] years) and have higher baseline acute physiology and chronic health evaluation (APACHE) II scores (mean [range]: 17 [0-28] vs. 15 [5-35]) than patients with solid tumors. Neutropenia [< or =500/microl] was present on entry in 23 (77%) patients with hematological malignancies and in one (3%) patient with a solid tumor. Candidemia was demonstrated in 56 (88%) cancer patients. C. albicans was the single most frequent isolate in cancer patients, although the majority of cases were caused by non-albicans species. Cancer patients in the caspofungin arm had more hematological malignancies (55 vs. 29%), higher baseline APACHE II scores (>20 in 36 vs. 15%), more frequent neutropenia (42 vs. 24%), and less C. albicans infections (27 vs. 49%) than the amphotericin B-treated cancer patients. Favorable response rates were 11/18 (61%) and 6/12 (50%) for patients with hematological malignancies treated with caspofungin or amphotericin B, respectively; the corresponding outcomes in patients with solid tumors were 12/15 (80%) and 17/29 (59%) for the 2 treatment arms. 7/14 (50%) caspofungin- and 4/10 (40%) amphotericin B-treated patients who were neutropenic on entry responded favorably. All-cause mortality rates during the study for caspofungin recipients were 11/18 (61%) with hematological malignancies and 6/15 (40%) with solid tumors, and for amphotericin recipients were 4/12 (33%) with hematological malignancies and 6/29 (21%) with solid tumors.
Conclusions: Underlying cancers, most commonly leukaemias and gastrointestinal tumors, were present in one-third of patients enrolled in this study of invasive candidiasis. Overall, 70% of caspofungin-treated and 56% of amphotericin B-treated cancer patients responded favorably. Response rates were lower for neutropenic leukaemic patients than for non-neutropenic patients with solid tumors in both treatment groups.
Similar articles
- Comparison of caspofungin and amphotericin B for invasive candidiasis.
Mora-Duarte J, Betts R, Rotstein C, Colombo AL, Thompson-Moya L, Smietana J, Lupinacci R, Sable C, Kartsonis N, Perfect J; Caspofungin Invasive Candidiasis Study Group. Mora-Duarte J, et al. N Engl J Med. 2002 Dec 19;347(25):2020-9. doi: 10.1056/NEJMoa021585. N Engl J Med. 2002. PMID: 12490683 Clinical Trial. - Invasive candidiasis treated in the intensive care unit: observations from a randomized clinical trial.
DiNubile MJ, Lupinacci RJ, Strohmaier KM, Sable CA, Kartsonis NA. DiNubile MJ, et al. J Crit Care. 2007 Sep;22(3):237-44. doi: 10.1016/j.jcrc.2006.11.004. Epub 2007 Apr 10. J Crit Care. 2007. PMID: 17869975 - Global distribution and outcomes for Candida species causing invasive candidiasis: results from an international randomized double-blind study of caspofungin versus amphotericin B for the treatment of invasive candidiasis.
Colombo AL, Perfect J, DiNubile M, Bartizal K, Motyl M, Hicks P, Lupinacci R, Sable C, Kartsonis N. Colombo AL, et al. Eur J Clin Microbiol Infect Dis. 2003 Aug;22(8):470-4. doi: 10.1007/s10096-003-0973-8. Epub 2003 Jul 23. Eur J Clin Microbiol Infect Dis. 2003. PMID: 12884068 Clinical Trial. - Efficacy of caspofungin against invasive Candida or invasive Aspergillus infections in neutropenic patients.
Betts R, Glasmacher A, Maertens J, Maschmeyer G, Vazquez JA, Teppler H, Taylor A, Lupinacci R, Sable C, Kartsonis N. Betts R, et al. Cancer. 2006 Jan 15;106(2):466-73. doi: 10.1002/cncr.21615. Cancer. 2006. PMID: 16353208 Review. - [Micafungin in invasive candidiasis among oncohematological patients].
Jarque I, Angel Sanz M. Jarque I, et al. Rev Iberoam Micol. 2009 Mar 31;26(1):75-7. doi: 10.1016/S1130-1406(09)70013-0. Epub 2009 May 7. Rev Iberoam Micol. 2009. PMID: 19463282 Review. Spanish.
Cited by
- Fungal infections in hematopoietic stem-cell transplant patients: a review of epidemiology, diagnosis, and management.
Rahi MS, Jindal V, Pednekar P, Parekh J, Gunasekaran K, Sharma S, Stender M, Jaiyesimi IA. Rahi MS, et al. Ther Adv Infect Dis. 2021 Aug 19;8:20499361211039050. doi: 10.1177/20499361211039050. eCollection 2021 Jan-Dec. Ther Adv Infect Dis. 2021. PMID: 34434551 Free PMC article. Review. - A real time PCR assay on blood for diagnosis of invasive candidiasis in immunocompromised patient.
Ashrafi M, Nabili M, Shokohi T, Janbabaie G, Hedayati MT, Ali-Moghaddam K. Ashrafi M, et al. Curr Med Mycol. 2015 Mar;1(1):35-41. doi: 10.18869/acadpub.cmm.1.1.35. Curr Med Mycol. 2015. PMID: 28680979 Free PMC article. - ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients.
Tissot F, Agrawal S, Pagano L, Petrikkos G, Groll AH, Skiada A, Lass-Flörl C, Calandra T, Viscoli C, Herbrecht R. Tissot F, et al. Haematologica. 2017 Mar;102(3):433-444. doi: 10.3324/haematol.2016.152900. Epub 2016 Dec 23. Haematologica. 2017. PMID: 28011902 Free PMC article. - Repurposing FDA approved drugs against the human fungal pathogen, Candida albicans.
Kim K, Zilbermintz L, Martchenko M. Kim K, et al. Ann Clin Microbiol Antimicrob. 2015 Jun 9;14:32. doi: 10.1186/s12941-015-0090-4. Ann Clin Microbiol Antimicrob. 2015. PMID: 26054754 Free PMC article. - A comparative histopathological study of systemic candidiasis in association with experimentally induced breast cancer.
Choo ZW, Chakravarthi S, Wong SF, Nagaraja HS, Thanikachalam PM, Mak JW, Radhakrishnan A, Tay A. Choo ZW, et al. Oncol Lett. 2010 Jan;1(1):215-222. doi: 10.3892/ol_00000039. Epub 2010 Jan 1. Oncol Lett. 2010. PMID: 22966285 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical